<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335437</url>
  </required_header>
  <id_info>
    <org_study_id>CEBA</org_study_id>
    <nct_id>NCT02335437</nct_id>
  </id_info>
  <brief_title>Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents</brief_title>
  <acronym>CEBA</acronym>
  <official_title>Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic fatigue syndrome (CFS) is characterized by unexplained, disabling and long lasting
      fatigue, as well as pain, impaired memory, sleep difficulties and other symptoms.
      Epstein-Barr virus (EBV) infection might precipitate CFS. In this study, 200 adolescents
      undergoing acute EBV infection will be followed prospectively, and also compared with a group
      of healthy controls. The aim is twofold:

        -  To identify factors that predispose to chronic fatigue among adolescents with acute EBV
           infection

        -  To compare pathophysiological features of patients with acute EBV infection with a group
           of healthy controls.

      Possible risk factors for chronic fatigue 6 months after EBV-infection includes:

        -  Severity of the initial infection

        -  Immune responses characteristics

        -  Characteristics of the neuroendocrine stress response

        -  Cognitive functioning

        -  Emotional disturbances

        -  Genetics/ epigenetics of candidate genes

        -  Certain personality traits

        -  Critical life events
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue</measure>
    <time_frame>6 monhts</time_frame>
    <description>Chalder fatigue questionnaire, total score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steps per day</measure>
    <time_frame>6 monhts</time_frame>
    <description>Mean number of steps/day across 7 consecutive days, measured by accelerometer (ActivePal)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain threshold</measure>
    <time_frame>6 monhts</time_frame>
    <description>Assessed by pressure algometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic cardiovascular control</measure>
    <time_frame>6 monhts</time_frame>
    <description>Assessed by noninvasive, continuous recordings of heart rate, blood pressures and stroke volume during supine rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>6 monhts</time_frame>
    <description>Assessed by the instruments WISC-IV, D-KEFS, HVLT-R and WASI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroendocrine markers</measure>
    <time_frame>6 monhts</time_frame>
    <description>In particular blood and urine measurements of catecholamines and the HPA axis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune markers</measure>
    <time_frame>6 monhts</time_frame>
    <description>In particular blood measurements of cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bodily symptoms</measure>
    <time_frame>6 monhts</time_frame>
    <description>Assessed by different questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 monhts</time_frame>
    <description>Assessed by the PedsQL inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional disability</measure>
    <time_frame>6 monhts</time_frame>
    <description>Assessed by the FDI inventory</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Fatigue Syndrome, Chronic</condition>
  <condition>Epstein-Barr Virus Infections</condition>
  <arm_group>
    <arm_group_label>Acute EBV infection</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Microbiological laboratories serving the population of Oslo and neighbour conties.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 12 years and &lt; 20 years

          -  Serological confirmation of acute EBV infection

          -  Lives in one of the following Norwegian counties: Oslo, Akershus, Buskerud, Østfold,
             Vestfold

        Exclusion Criteria:

          -  Medical treatment for another disease (hormonal conterception and antibiotics against
             tonsillitis/pharyngitis are accepted)

          -  Pregnancy

          -  Debut of illness &gt; 6 weeks ago
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vegard B Wyller</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Pediatrics, Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <state>Akershus</state>
        <zip>N-1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://www.ahus.no/omoss_/avdelinger_/barne--og-ungdomsklinikken_/forskning_og_utvikling_/Sider/CEBA.aspx</url>
    <description>Information on the project, including complete Study Protocol and Statistical Analysis Plan</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2015</study_first_submitted>
  <study_first_submitted_qc>January 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2015</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Vegard Bruun Wyller, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

